+

WO1992003127A1 - Compositions et procedes pour le traitement des infections par le vih - Google Patents

Compositions et procedes pour le traitement des infections par le vih Download PDF

Info

Publication number
WO1992003127A1
WO1992003127A1 PCT/US1991/005919 US9105919W WO9203127A1 WO 1992003127 A1 WO1992003127 A1 WO 1992003127A1 US 9105919 W US9105919 W US 9105919W WO 9203127 A1 WO9203127 A1 WO 9203127A1
Authority
WO
WIPO (PCT)
Prior art keywords
trna
composition
acid
composition according
thiolated
Prior art date
Application number
PCT/US1991/005919
Other languages
English (en)
Inventor
Thomas J. Bardos
Yau-Kwan Ho
Janos Aradi
Raymond F. Schinazi
Original Assignee
Research Foundation Of The State University Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation Of The State University Of New York filed Critical Research Foundation Of The State University Of New York
Publication of WO1992003127A1 publication Critical patent/WO1992003127A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Definitions

  • This invention relates to novel compositions and meth ⁇ ods for treating HIV infections.
  • this inven ⁇ tion relates to novel thio-containing ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) wherein the RNA and DNA derivatives contain thiol groups in reduced or oxidized for at the five position of the pyrimidine ring of monomeric units which comprise the RNA and DNA derivatives.
  • a method for treating HIV infections is presented.
  • HTLV I Human T-cell leukemia lymphotropic virus
  • This virus is etiologically associated with adult T-cell leukemia (See, for example, Gallo, et al. Blood, 60, 545 (1982)).
  • a related but distinct retrovirus, HTLV-II was iso ⁇ lated from a T-cell variant of hairy cell leukemia (See Kalyanaraman, et al.. Science. 218, 571 (1982). Both of these viruses have exhibited a tropism for human 0KT4+ cells and have the capacity to immortalize and transform normal human T- cells in culture (Miyoshi, et al.. Nature (Lond. ) . 294, 770 (1981) and Popovic, et al., Proc. Natl. Acad. Sci. USA. 80, 5402 (1983)).
  • AIDS Autoimmune Deficiency Syndrome
  • Gallo, et al., Science. 224, 500 (1983) is recognized as the first investiga ⁇ tor to isolate and characterize a retrovirus associated with AIDS which is biologically and morphologically distinct from HTLV I and II. Due to certain homologous gene sequences between the AIDS associated virus and HTLV I and II, this virus has been termed HTLV III (HIV 1) .
  • Another retrovirus, termed lymphoadenopathy virus (HIV 2) has also been shown to be associated with AIDS (Ellrodt, et al..
  • HTLV I and II T-lymphotropic retroviruses
  • HTLV III HBV-1
  • lymphoadenopathy viruses are nontransforming cytopathic viruses without immortalizing activity.
  • the viral replication process is believed to be an important event in the progress of AIDS.
  • the enzyme RNA-Directed DNA polymerase or "Reverse" Transciptase may be implicated in the progress of the disease (Chandra, et al., Cancer Res. , 45, 4677s-4684s (1985) ) and that this enzyme may be an interesting target for the development of potential drugs against AIDs.
  • the above paper includes some interesting results with selec ⁇ tive inhibitors (including modified polycytidylic acid (MPC)) of a reverse transriptase purified from HTLV-III and from HTLV-III infected H9 cells.
  • selec ⁇ tive inhibitors including modified polycytidylic acid (MPC)
  • HIV-1 virus One of the more significant biological properties of the HIV-1 virus is its ability to integrate a DNA copy of its diploid RNA genome into the chromosome of the host cell. This means that once a single cell in a person has been infected with the AIDS virus, the viral genetic information will be carried indefinitely. Relatively few of the infected cells are actually killed by HIV-1, thus the cells continue to release fresh virus and infect further cells. Some infected cells have a short half-life of days or weeks, but certain infected cells, for example, dendritic macrophage cells may live for decades. Although numerous cells in circulation may be infected, perhaps only 1 cell in 10,000 is actually activated at any one time to produce the virus to infect other cells.
  • RNA tumor viruses can utilize complexes of certain homopolyribonucleotides with the complementary oligodeoxyribonucleotides as template-primers (See Sarngad- haran, et al., Methods Cancer Res. , 12, 3 (1976)).
  • Numerous successful attempts to inhibit the reverse transcriptases from various RNA tumor viruses with the use of macromolecular antimetabolites such as 5-Mercaptopolyuridylic acid (MPU) and 5-Mercaptocytidylic acid (MPC) have also been reported (See, for example, Kung, et al.. Res. Comm. Chem. Path. Pharm.
  • Reverse transcriptase is a DNA polymerase located in the core fraction of the virus complexed with viral RNA. In this ribonucleoprotein containing reverse transcriptase, the transcription of viral RNA into a complementary DNA occurs (See Chandra, et al., Cancer Res. f 45, 4677s-4684s (1985)). RNA directed DNA synthesis is unique to the life cycle of retroviruses; no similar reaction is known to occur in normal, uninfected human tissues.
  • Reverse transcriptase is a multifunctional enzyme, comprising at least four domains that reportedly mediate RNA dependent DNA polymerase activity, RNase H activity, and DNA dependent DNA polymerase activity and a site for nucleic acid binding.
  • the final product of the reactions mediated by reverse transcriptase is a linear double stranded DNA contain ⁇ ing long terminal repeat units written as 5'-U3-TR-U5-3' pres ⁇ ent at both ends of the DNA. (See Chandra, et al., supra) .
  • the present invention relates to a novel method for treating HIV infected cells and HIV infections comprising administering to a patient suffering from an HIV infection an effective amount of a thiol-containing composition selected from among 5-Thiolated oligo(deoxy)ribonucleotides and 5- Thiolated polynucleotides.
  • a thiol-containing composition selected from among 5-Thiolated oligo(deoxy)ribonucleotides and 5- Thiolated polynucleotides.
  • These compositions have shown sur ⁇ prising activity against HIV-I infections in vivo (HIV infected human T-lymphocytes) indicating that the 5-Thiolated poly- and oligo- nucleotide compositions are therapeutically effective agents for inhibiting HIV-I infections and for treating AIDS.
  • the compositions of the present inven ⁇ tion have evidenced a virtual absence of toxicity in human cell systems.
  • the present invention also relates to novel 5- Thiolated oligo and poly nucleotides compositions which are particularly useful as therapeutic agents for treating HIV infections.
  • Compositions of the present invention have shown surprising activity in being able to inhibit HIV infections in vivo (human T-Lymphocytes) .
  • the present invention also relates to pharmaceutical compositions comprising the 5-Thiolated oligo- and polynucleotides of the present invention in therapeutically effective amounts, optionally in the presence of pharamceuti- cally compatible additives and/or excipients.
  • Pharmaceutical compositions of the present invention are preferably administered via a parenteral route, for example via intravenous, intraarterial, intramuscular and subcutaneous routes.
  • compositions of the present invention may also be used as disinfectants to treat HIV infected areas such as laboratory equipment, laboratory surfaces and other areas.
  • Figure 1 represents the chemical structure of three isoaccepting tRNA L y s (tRNA L y s l,2; tRNA L y s 3 and tRNA L y s 4 which are thiolated to produce partially 5-Thiolated tRNA L y s of the present invention.
  • 5-Thiolated oligonucleotide is used to describe a DNA or RNA molecule containing about 5 to about 100 nucleotide units wherein at least one pyrimidine nucleoside of the DNA or RNA molecule, i.e., a cytidine or uridine nucleoside is substituted at the 5 position of the pyrimidine ring with a thiol or SH group.
  • the term as used embraces RNA and DNA molecules each containing the four most abundant naturally occurring nucleosides, respectively, i.e.
  • guanosine, adenosine, uridine and cytidine in the case of RNA and 2'-deoxyguanosine, 2'-deoxyadenosine, 2'-deoxythymidine and 2 -deoxycytidine in the case of DNA, as well as other less abundant nucleosides such as, for example pseudouridine, methyl cytidine and methyl guanosine, among others.
  • RNA molecule ribose sugar
  • RNA molecule ribose sugar
  • 5-Thiolated oligodeoxyribonucleotide is used to describe a DNA molecule (2 / -deoxyribose sugar) con ⁇ taining about 5 to about 100 nucleotide units wherein at least one pyrimidine 2'-deoxynucleoside (2 -deoxycytidine or 2'- deoxyuridine) is substituted at the 5 position with a thiol or SH group.
  • 5-Thiolated polynucleotide is used to des ⁇ cribe a DNA or RNA molecule containing at least about 100 nucleotide units wherein at least one pyrimidine nucleoside per 100 total nucleosides (purine and pyrimidine) of the DNA or RNA molecule is substituted at the 5 position of the pyrimidine ring with a thiol or SH group.
  • RNA molecule containing at least about 100 nucleotide units wherein at least one pyrimidine nucleoside per 100 tott nucleosides of the RNA molecule is substituted at the 5 position of the pyrimidine ring with a thiol or SH group.
  • 5-Thiolated polydeoxyribonucleotide is used to describe a DNA molecule containing at least about 100 nucleotide units wherein at least one pyrimidine nucleoside per 100 total nucleosides of the RNA molecule is substituted at the 5 position of the pyrimidine ring with a thiol or SH group.
  • regional oligonucleotide is used to des ⁇ cribe a DNA or RNA molecule corresponding to a specific region on the primer tRNA of HIV reverse transcriptase, tRNA L y s .
  • the term includes oligonucleotides which are anti-sense to specific tRNA regions.
  • Regional oligonucleotides for use in the present invention may include nucleotides which occur naturally in the tRNA such as the methylated nucleotides and pseudonucleotides, among others, as well as nucleotides which may function as substitutes for the naturally occuring nucleotides within the regional oligonucleotide.
  • 5-Mercaptopolycytidylate is used to define a polyribonucleotide comprised of more than 100 nucleotide units of cytidylic acid in general containing a majority (>50%) of unthiolated nucleotide units and a minority ( ⁇ 50%) of thiolated nucleotide units.
  • MPC Mercaptopolydeoxycytidylate
  • 5-Mercaptopolyuridylate is used to define a polyribonucleotide comprised of more than 100 nucleotide units of uridylic acid in general containing a majority (>50%) of unthiolated nucleotide units and a minority ( ⁇ 50%) of thiolated nucleotide units.
  • Mercaptopolydeoxyuridylate is the 2'-deoxy version of MPU.
  • the term "5-Mercaptooligocytidylate” (MOC) is used to define an oligoribonucleotide comprised of less than 100 nucleotide units of cytidylic acid in general containing a majority (>50%) of unthiolated nucleotide units and a minority ( ⁇ 50%) of thiolated nucleotide units.
  • MOC Mercaptooligodeoxycytidylate
  • 5-Mercaptooligouridylate (MOU) is used to define an oligoribonucleotide comprised of less than 100 nucleotide units of uridylic acid in general containing a majority (>50%) of unthiolated nucleotide units and a minority ( ⁇ 50%) of thiolated nucleotide units.
  • Mercaptooligodeoxyuridylate (MOdU) is the 2'-deoxy version of MOU.
  • thiol and thiolated are used to describe sulphur substitution at the five position of a pyrimidine nucleoside includes thiol groups (SH) , mercaptide groups (S_) and disulfides (-S-S-) formed from the oxidation of thiols or mercaptides on thiolated nucleoside units of the RNA or DNA.
  • n-mer is used to describe an oligomer con ⁇ taining n nucleotide units.
  • homopolymer and “homooligomer” is used to describe RNA and DNA molecules which are made from the same nucleotide.
  • Poly(C) , poly(U) and oligo(T) are examples of homopolymers and a homooligomer, respectively.
  • the present invention relates to a therapeutic method for treating HIV infections.
  • a patient suffering from an HIV infection includ ⁇ ing a patient with AIDS, is administered an effective amount of a thiol-containing composition selected from among 5- Thiolated oligo(deoxy)ribonucleotides and 5-Thiolated polynucleotides.
  • 5-Thiolated polynucleotides that can be used in the present invention include.the 5-Thiolated homopolyribonucleotides 5-Mercaptopolycytidylic acid (MPC) and 5-Mercaptopolyuridylic acid (MPU) as well as 5-Thiolated homopolydeoxyribonucleotides 5-Mercaptopolydeoxycytidylic acid (MPdC) and 5-Mercaptopolydeoxyuridylic acid (MPdU) with MPdC and MPdU preferred because of .their significantly enhanced activity relative to MPC and MPU as anti-HIV therapeutic agents. It is an unexpected result that MPdC and MPdU exhibit such enhanced anti-HIV activity relative to MPC and MPU. It is also a surprising result that MPdU exhibits significantly more anti-HIV activity than does the corresponding MPU.
  • pyrimidine nucleoside per 100 total nucleosides is thiolated.
  • a thiolation content of about 5 to about 15 thiolated pyrimidine nucleosides per 100 total nucleosides thiolation content about 5% to about 15%
  • a thiolation content ranging from about 8% to about 12% being especially preferred.
  • Oligoribonucleotides that may be used in the present invention include 5-Mercaptooligocytidylic acid (MOC) and 5- Mercaptooligouridylic acid (MOU) .
  • Oligodeoxyribonucleotides that may be used in the present invention include 5- Mercaptooligodeoxycytidylie acid (MOdC) and 5- Mercaptooligodeoxyuridylic acid (MOdU) , with the oligodeoxyribonucleotides being significantly more active than the corresponding oligoribonucleotides.
  • the oligonucleotides range in size from about 5 nucleotide units to about 100 nucleotide units with a preferred range of about 25 to 50 units and a most preferred range of about 35 to 45 nucleotide units.
  • oligodeoxyribonucleotides evidence unexpectedly greater anti-HIV activity than do the corresponding oligoribonucleotides and are clearly preferred for use in the present invention because of this enhanced activity.
  • the amount of thiolation generally ranges from about 2% to about 25% of the oligonucleotide, with a range of about 5% to about 10% thiola ⁇ tion being preferred.
  • the present invention also relates to 5-Thiolated oligonucleotides which correspond to certain regions of an HIV reverse transcriptase primer tRNA, and in particular tRNALy S .
  • 5-Thiolated oligonucleotides preferably oligodeoxyribonucleotides, corresponding to the anti-codon region (represented in its deoxy form as 5-Mercapto 5'- d(ATC/AGA/CTT/TTA/ATC/TGA)-3 / ) or the 3'terminus (represented in its deoxy form as 5-Mercapto 5'-d(GTC/CCT/GTT/CGG/GCG/CCA)- 3') of the tRNALy S , among others, are useful for treating HIV infections.
  • the present invention relates to "anti-sense" 5-Thiolated oligonucleotides of the regions of the tRNAj j ys described above, for example, the anti-sense to the 3'terminus region described above (represented in its deoxy form as 5-Mercapto 5'-d(TGG/CGC/CCG/AAC/AGG/GAC)- 3') or the anti-sense to the anti-codon region set forth above (represented in its deoxy form as 5-Mercapto 5'- d(TCA/GAT/TAA/AAG/TCT/GAT)-3') .
  • 5-Thiolated oligonucleotides corresponding to a region of the primer tRNA containing from about 5 to about 20 nucleotide units, and preferably from about 12 to about 18 nucleotide units are utilized.
  • oligo(deoxy)ribonucleoitdes containing more than about 20 nucleotide units do not add to the anti-HIV activity of the composition.
  • the deoxyribonucleotide is preferred over the corresponding ribonucleotide because of its enhanced anti-HIV activity.
  • 5-Thiolated oligonucleotides comprising a non-thiolated (binding) homooligonucleotide region to pro- mote the binding of the remaining portion of the 5-Thiolated oligonucleotides to a homopurine (or homopyrimidine) site of the viral genome via triple-helix formations, are disclosed.
  • the non-thiolated homooligonucleotide regions which promote binding to the HIV genome via triplex formation include, for example, homooligomers such as oligo(deoxy)adenylate and oligothymidy- late bound at the 5' end of 5-Thiolated oligo(deoxy)cytidylic or uridylic acid.
  • the binding homooligonucleotide portion which is preferably not thiolated, ranges in size from about 5 nucleotide units to about 25 nucleotide units with 10-15 nucleotide units preferred.
  • this por ⁇ tion of the compositions generally ranges in size from about 5 nucleotide units to about 50 nucleotide units, with about 20 units to about 30 nucleotide units being preferred.
  • the amount of thiolation of this portion of the composition generally ranges from 1 thiolation to about 15% total thiola ⁇ tion, with a lower amount ie. , about 1 to 3 thiols per oligomer preferred.
  • the deoxyribonucleotides are preferred over the corresponding ribonucleotides.
  • the structures of certain representative compositions appear below. The follow ⁇ ing list is, of course, by no means complete.
  • 5- Thiolated homooligonucleotides are bound to the previously described regional oligonucleotides of the primer tRNAj j ys.
  • These 5-Thiolated homooligonucleotides which range in length from about 5 to about 50 nucleotide units and preferably about 20 to about 40 nucleotide units, may be bound to the regional oligonucleotides at the 5' or 3' end.
  • the amount of thiola ⁇ tion of these homooligomers generally ranges from 1 thiolation to about 15% thiolation, with about 3% to about 10% thiolation being preferred.
  • the deoxyribonucleotides are preferred over the corresponding ribonucleotides because of their greater activity.
  • the structures of certain representative composi ⁇ tions of the present invention appear below.
  • Each of these compositions comprises an 18-mer regional oligonucleotide and a 22-mer thiolated homooligomer for a total of 40 nucleotide units. The following list is, of course, by no means com ⁇ plete.
  • 5-Mercapto oligodeoxyribonucleotides the ribonucleotide analogs may also be used as well as shorter regional oligomers and shorter 5- Thiolated homooligomers. These agents are presently viewed as less preferred because of the difficulties attached to the synthesis of oligoribonucleotides in general and especially those greater than about 20 units.
  • 5-Thiolated tRNAs including, for example, tRNA L y s are useful fc - treating HIV infections. In the present inven ⁇ tion, mixtures of 5-Thiolated tRNAs were found to be highly effective in vivo against HIV infections.
  • 5-Thiolated tRNAs which bind to the primer binding region of the HIV-genome as well as to the HIV reverse transcriptase.
  • 5-Thiolated tRNA L y s (iso ⁇ lated from sheep liver and thiolated according to literature procedure) exhibited significantly enhanced anti-HIV activity in vivo, perhaps also due to the ability of the tRNA L y s to bind to the primer binding region of the HIV proviral DNA as well as to the HIV reverse transcriptase.
  • compositions of the present invention include thiolated enzymatically lysed segments of primer tRNA, preferably tRNA L y s which correspond to segments of the primer tRNA. After enzymatic degradation of the primer tRNA, these oligomers are isolated and then thiolated, or alternatively, thiolated and then isolated. The resulting thiolated oligonucleotides correspond to sense or anti-sense regions of the primer tRNA or proviral genome and are useful as anti-HIV agents. These thiolated oligoribonucleotides range in size from about 5 nucleotide units to about 45 nucleotide units, with a range of about 20 nucleotide units to about 40 nucleotide units being preferred.
  • compositions of the present invention procedures well known in the art are employed.
  • the isolated homopolymer (enzymatically synthesized by the general method ⁇ ology described below) is thiolated according to the general chemical method (methoxybromide procedure) of Bardos, et al., Nucleic Acid Chemistry , Vol. 2, 881 (1978); Ho, et al., Biochem. Biophys. Res. Comm.. 73, 903 (1976); and Mikulski, et al., Biochim. Biophys. Acta. , 319, 294 (1973).
  • the amount of thiolation may be readily controlled for these as well as other compositions of the present invention by the stoichiometry of the methoxybromination and thiolation reac- tions.
  • the homoribopolymers PolyC and Poly U may also be synthesized by the enzymatic polymerization of the correspond ⁇ ing monomeric ribonucleoside-5'-diphosphates using the polynucleotide phosphorylase of . coli or M ⁇ .
  • poly d(C) and poly d(U) are normally obtained by polymeriza ⁇ tion of the deoxyribonucleoside-5'-triphosphates with the enzyme terminal deoxyribonucleotidyl transferase (tdt) .
  • Thiolation is produced by the above-referenced methoxybromide procedure.
  • the 5-Thiolated homopolynucleotide compositions may be synthesized directly by an enzymatic method.
  • MPC and MPU are synthesized via enzymatic copolymerization of the 5'-diphosphates of 5-mercaptouridine and uridine or 5-mercaptocytidine and cytidine as described by Ho, et al., Nucleic Acid Research. 8, 3175 (1980).
  • MPdC and MPdU are synthesized by copolymerizing the respective 5'- triphosphates with the enzyme tdt described above.
  • 5-Thiolated homooligoribonucleotides are prepared by partial alkaline hydrolysis of Poly(C) or Poly(U) followed by chromatographic separation on DEAE cellulose according to the procedure of Ho, et al., Biochem. Biophys. Res. Commun.. 73, 903 (1976) . After the respective molecular weight fractions of the homooligomers are isolated, they are subsequently thio ⁇ lated by the methoxybromide method referenced above to produce MOC or MOU.
  • 5-Thiolated homooligodeoxyribonucleotides are prepared via a step-wise chemical synthesis of OdC or OdU according to the phosphoramidite procedure or related procedures as dis ⁇ closed by Gait, M.J., Ed.: Oligonucleotide Synthesis. A Prac ⁇ tice Approach. IRL Press, Oxford, England (1984) , such as via an automated DNA synthesizer (such as that system available from Applied Biosystems, Inc., USA Model 381A) or by a manual solid-phase synthetic method.
  • 5-Thiolation proceeds according to the previously cited methoxybromide thiolation method according to literature methods.
  • 5-Thiolated oligoribonucleotides such as those cor ⁇ responding to the anti-codon and 3'terminus regions of tRNA Lvs as well as 5-Thiolated oligoribonucleotides anti-sense to those regions (up to 20 nucleotide units) are synthesized via the method as disclosed by Lehmann, et al., Nucl. Acids Res., 17, 2379 (1989) as well as other methods known in the art.
  • 5-Thiolated tRNA mixtures especially including, for example, 5-Thiolated tRNA- ⁇ y* 3 compositions are made by first isolating mixed aminoacid-tRNAs from animal liver, for exam ⁇ ple, sheep liver because of its rich tRNA L y s and bovine liver according to literature procedure (Rogg, et al., Biochim. Biophys. Acta. 195, 13, (1969)) and then thiolating the tRNA mixture by the above-referenced methoxybromide procedure.
  • 5- Thiolated tRNA L y s is prepared by first isolating tRNA L y s and thiolating the tRNA.
  • the tRNA L y s is isolated from sheep by extraction of the protein with phenol to produce a protein-free mixture of tRNAs, followed by column chromatraphy (DEAE sephadex) according to the above literature reference.
  • Two tRNA L Y s fractions are isolated, tRNA L y s 1;2 and tRNA L Y s 3 (see figure 1) and one tRNA L y s poor fraction between the two tRNA L Y s enriched fragments is also isolated.
  • a tRNA :L y s 4 fragment can be isolated from rapidly proliferating cells, also isolated from Sheep liver. Once isolated, the tRNA L y s are thiolated according to general pro ⁇ cedure referenced above and described in the literature.
  • a primer tRNA preferably tRNA L s is isolated as described above and then subject to degradation by 1 RNase according to the procedure described in Bordier, et al., Nucleic Acid Res ⁇ , 18, 429 (1990) followed by isolation.
  • the isolated oligoribonucleotides are subsequently thiolated according to the above-described procedure and used as anti-HIV agents.
  • the previously described 5-Thiolated poly or oligonucleotide compositions may* be formulated in pharmaceuti ⁇ cal compositions.
  • Such compositions include an anti-HIV effective amount of the 5-Thiolated poly or oligonucleotide compositions optionally in the presence of pharmaceutically compatible excipients and additives.
  • compositions of the present invention may be used to treat HIV infections.
  • an amount of a 5-Thiolated poly or oligonucleotide as previously described is administered to a patient suffering from an HIV infection in an amount effective to treat the HIV infection.
  • the previously described 5- Thiolated poly and oligonucleotides of the present invention may be administered to a subject such as a human patient, for the treatment of HIV infections.
  • the prescribing physician will ultimately determine the appropriate dose for a given human subject, and this can be expected to vary according to the age, weight, and response of the individual as well as the nature and severity of the patient's disease.
  • compositions of the present invention may be combined with 3'-azido-3'- deoxythymidine (AZT) , 2',3'-dideoxycytidine (DDC) or other anti-HIV compositions which have a mechanism of action which differs from those of the present invention as a therepeutic method.
  • AZT 3'-azido-3'- deoxythymidine
  • DDC 2',3'-dideoxycytidine
  • other anti-HIV compositions which have a mechanism of action which differs from those of the present invention as a therepeutic method.
  • the amounts of the 5-Thiolated poly or oligonucleotides used as well the AZT or DDC, among other agents will generally be less than when each agent is used alone because of the synergistic therapeutic effect exhibited by the combination of agents.
  • the mode of administration may determine the sites in the organism to which the compound(s) will be delivered. For instance, delivery to a specific site of activity may be most easily accomplished by parenteral administration, for example, by injection via intraperitoneal, intravenous, intraarterial, intramuscular, subcutaneous or related routes.
  • the preferred route of administration is via an intravenous or intraarterial route.
  • the thiol-containing compositions of the present invention may best be used in the form of liposomes or a sterile aqueous solution which may con ⁇ tain other solutes, for example, sufficient salts, glucose or dextrose to make the solution isotonic.
  • the thiol-containing compositions according to the present invention may be administered alone but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • polylysine is complexed or conjugated with the 5-Thiolated compositions of the present invention.
  • an oral mode of administration in which case the thiol-containing composi ⁇ tions of the present invention can be used in the form of tablets, capsules, lozenges, troches, powders, syrups, elixirs, aqueous solutions and suspension, and the like.
  • carriers which can be used include lac ⁇ tose, sodium citrate, and salts of phosphoric acid.
  • disintegrants such as starch, and lubricating agents, for example, stearic acid may be used.
  • useful diluents are lactose and high molecular weight polyethylene glycols.
  • compositions of the present invention which are intended to be administered via an oral route may be unstable to the harsh conditions of the gastrointestinal tract, especially due to the existence of nucleases which tend to degrade the composi ⁇ tions of the present invention.
  • nucleases which tend to degrade the composi ⁇ tions of the present invention.
  • one of ordinary skill in the art will recognize to formulate the oral formulations to avoid the release of the compositions under conditions which render them unstable, for example, the extremely acidic conditions of the stomach.
  • the compositions according to the present invention may be administered as the phosphotriester prodrug form (methyl or ethyl ester) .
  • the use of calcium or quarternary ammonium salts of the phosphates including the cetyltrimethylammonium salt, among others may advantageously be used orally.
  • thiol-containing compositions described hereinabove including their pharmaceutically acceptable salts, are contemplated for use in the present invention. Determination of the amounts and compatibilities of the above listed biologically active agents which are used to formulate the pharmaceutical compositions of the present invention are well within the ordinary skill in the formulation art. The stability and applicability of individual pharmaceutical agents are well within the ordinary skill of the practitioner in this art.
  • the amount of the thiol-containing com ⁇ positions which are administered to the patient will be an effective amount and will range from about O.lmg. to about 100 mg. per kg. weight of the patient to be treated.
  • the dosage administered to the patient to be treated will range from about 0.1 mg. to about 50 mg. per kg.
  • the amount of thiol-containing composition administered to the patient will range from about 1 mg. to about 20 mg. per kg. Dosages within these ranges should attain blood levels of active agent of at least about 1-10 urn. In certain cases, in the treatment of HIV infections in humans, the concentration of active agent may attain blood levels of 50-100 um. or more.
  • compositions according to the present invention have exhibited low toxicity to normal cells.
  • Certain Thiol-containing compositions according to the present invention have been screened for their potential toxic effects on uninfected PHA-stimulated human PBM cells using a radioac ⁇ tive thymidine uptake method. In that method, cells in a 96- well plate were grown in the presence of drug for 24 hours, and then 1 uCi of [ 3 H]-thymidine was added to each well. After 24 hours, the cells were harvested on glass fibers, washed, dried, and the amount of radioactivity associated with the cells was determined. Cycloheximide was included as a control for toxicity in every assay. Inhibitory concentra- .
  • tions (ID5 0 ) values for normal human PBM cells were derived from a computer-generated median effect plot of dose-effect data. Compositions according to the present invention exhibited very low toxicity (ID5 0 ranged from 38.2 to > 100 mg./ml. and in most instances was > 100 mg./ml.).
  • the actual preferred amounts of the thiol-containing compositions of the present invention utilized in a specific case may vary according to the severity of a disease condition and the expected pharmacokinetics of the compositions in the individual patient. Dosages for a given host can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the subject bioactive agent by means of an appropriate, conventional pharmacological protocol.
  • a patient with an HIV infection will be treated by administering an effective amount of a thiol-containing com ⁇ position of the present invention by an oral, topical or parenteral, preferably intravenous route.
  • the duration of treatment may vary considerably, but will generally range as a function of the response of the individual patient to the treatment schedule.
  • poly(C) , Poly(U) and Poly (dC) obtained from Pharmacia, New Jersey, USA or alternatively via enzymatic synthesis according to lit ⁇ erature procedures, was converted to the cetyltrimethylam- monium salt using cetyltrimethylammonium bromide (dropwise addition) .
  • the precipitated cetyltrimethylammonium poly(cytidylate) was collected by centrifugation, washed with distilled water, dissolved in methanol and evaporated to dry- ness. The residue was dried in vacuo overnight. To a solu ⁇ tion of the dry salt in anhydrous methanol is added methyl hypobromite and the mixture was stirred for 30 minutes at 0°C.
  • MPC and MPU were synthesized according to the methods described by Ho, et al., in Nucleic Acids Res.. 8, 3175
  • Uridine 5'-diphosphate UDP
  • Cytidine 5'- diphosphate CDP
  • 5-Thiolated diphosphate i.e. either 5-Mercaptouridine-5'-diphosphate
  • the reaction mixture was incubated at 48°C for about 8 hours The percentage of polymerization was followed by assaying for inorganic phosphate by the method of Chen, et al., Anal. Chem. , 28, 1756 (1956); blank was subtracted from the readings. After incubation, the solution was deprotenized by repeated extraction with chloroform-isoamyl alcohol (5:3). The polynucleotide was purified by chro atography through Sephadex G-100 in the presence of mercaptoethanol.
  • thiolated base incorporated into the polymeric products were determined based on the UV absor- saye of the 5-mercaptopyrimidine derivative at 334 nm in the presence of dithiothreitol at pH 8.0.
  • the resulting thiolated polynucleotides were used in the assay of example 7, below.
  • the hydrolyzed poly(C) was loaded onto a column of DEAE cellulose (bicarbonate form, 2.5 cm X 20 cm) and eluted with 250 ml each of 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.7 & 1.0 M TEAB buffer (pH 7.6-8.0). These fractions were monitored by TLC (solvent system (n-propanol/NH 3 /H 2 0 55:33:10 v/v) against the standard 5'-CMP and poly(C) . Each fraction contains several oligomers of chain-lengths within 10 monomer units (+ 10-mers) .
  • Partial thiolation of the oligomers was carried out in accordance with the standard procedure as described by Bardos, .J. , et al. , Biochim. Biophys. Acta. 319, 294 (1973) . This procedure resulted in the formation of 5-Thiolated oligoribonucleotides which are subsequently tested. in vivo for anti-HIV activity.
  • oligonucleotides are synthesized by the same method as described in Example 4, above and tested for anti-HIV activity.
  • oligodeoxyribonucleotides corresponding to the anti-codon or 3' terminus region of tRNAj j ys or anti- sense oligodeoxyribonucleotides to the same regions are synthesized by the method described above and tested for anti- HIV activity jLn vivo as described in the following examples 7 and 8:
  • a mixture of tRNAs is separated from sheep liver according to the procedure of Rogg, et al., Biochim. Biophys. Acta, 195, 13 (1969) . A portion of this mixture is subse ⁇ quently thiolated by the procedure set forth in example 1. The 5-Thiolated tRNAs were subsequently tested for anti-HIV activity in vivo.
  • 5-Thiolated polynucleotides were synthesized and tested against HIV 1 virus in vivo.
  • these modified polynucleotides were synthesized by the thiolation (methoxybromide method) of preformed homopolynucleotides or by co-polymerization of 5-Mercapto-Uridine-5'-diphosphate and uridine-5'-diphosphate or adenosine-5'-diphosphate by polynucleotide phosphorylase as described in Example 2, above.
  • the following 5-Thiolated poly(deoxy)nucleotides were made and tested: poly(U 91 ,hs5u 9 )
  • H 9 human lymphocytes were infected with diluted (1 to 10 and 1 to 32) standard HIV 1 (HTLV-III 3 ) suspension (2000 virus particles per cell). After a 90 minute incubation period at 37°C the unadsorbed viruses were rinsed off. The washed cells were then resuspended in culture media (10 5 cells/ml) and dispensed in 2 ml por t ions onto Costar 24-well plates. Cc. ⁇ rol cells were treated similarly but were not exposed to the virus. To determine the inhibitory activities of various chemically modified polynucleotides and control materials (AZT and Phosphonoformic acid (PFA or Foscarnet) ) the indicated con ⁇ centrations of drugs were added (See Table 1, below) .
  • AZT and Phosphonoformic acid (PFA or Foscarnet) the indicated con ⁇ centrations of drugs were added (See Table 1, below) .
  • the inhibitory activites of the drugs on replication of HIV 1 were evaluated by the following methods.
  • Polynucleotide fuM Mon. Unit Unit) Poly(U 91 ,hs 5 U 9 ) 1
  • Virus concentration was about 63,000 disintegrations per minute of RT activity per 10 7 cells per mL of medium.
  • the drugs were added about 45 minutes after infection.
  • the cultures were maintained in a humidified 5% C0 2 - 95% air incubator at 37°C for six days after infection at which point all cultures were sampled for supernatant RT activity.
  • the supernatant was clarified, and the virus particles were pelleted at 40,000 rpm for 30 minutes using a rotor (70.1 Ti; Beckman Instr. , Fullerton, CA.) and suspended in virus disrupting buffer.
  • RT assay was per- formed in 96-well microdiluation plates using poly(rA) n -(dT)- 12-1 2; as template- p rimer.
  • 3'-Azido-3'-deoxythymidine (AZT) was included in ee h as- y as a positive control.
  • d(/CAG/ACT/TTT/AAT/CTG/AGC) is the anticodon analog of t- RNA L Y S 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à un nouveau procédé thérapeutique de traitement des infections par le VIH, qui consiste à administrer à un patient affecté par le VIH une quantité efficace d'une composition contenant du thiol choisi parmi des oligonucléotides thiolés en position 5 et des polynucléotides thiolés en position 5. Ces compositions se sont révélées déployer une activité surprenante contre les infections par le VIH-I in vivo (lymphocytes T humains affectés par le VIH), ce qui indique que les compositions de polynucléotides et d'oligonucléotides thiolés en position 5 constituent des agents thérapeutiques efficaces d'inhibition des infections par le VIH-I et le traitement du SIDA.
PCT/US1991/005919 1990-08-16 1991-08-15 Compositions et procedes pour le traitement des infections par le vih WO1992003127A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56813190A 1990-08-16 1990-08-16
US568,131 1990-08-16

Publications (1)

Publication Number Publication Date
WO1992003127A1 true WO1992003127A1 (fr) 1992-03-05

Family

ID=24270037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/005919 WO1992003127A1 (fr) 1990-08-16 1991-08-15 Compositions et procedes pour le traitement des infections par le vih

Country Status (2)

Country Link
AU (1) AU8497191A (fr)
WO (1) WO1992003127A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003528A2 (fr) * 1994-07-27 1996-02-08 Cambridge University Technical Services Limited Oligonucleotides et leur utilisation
EP1015011A1 (fr) * 1997-09-16 2000-07-05 NIELSEN, Peter Eigil Acides nucleiques peptidiques a activite antibacterienne
EP1466988A3 (fr) * 1998-06-11 2006-06-07 Chiron Corporation Gènes et produits d'expression génique régulés de façon différentielle lors du cancer de la prostate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Volume 73, No. 4, issued 1976, Y.K. HO et al., "Oligonucleotides Containing Modified Bases", see pages 903-910. *
BIOCHIMICA ET BIOPHYSICA ACTA, Volume 319, issued 1973, MIKULSHI et al., "Inhibition of DNA-dependent RNA Polymerase with partialy Thiolated Polynucleotides", pages 294-303. *
NUCLEIC ACIDS RESEARCH, Vol. 8, No. 14, issued 1980, Y.K. HO et al., "Enzymatic synthesis of Polyuridylic Acid containing modified Bases", see pages 3175-3191. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003528A2 (fr) * 1994-07-27 1996-02-08 Cambridge University Technical Services Limited Oligonucleotides et leur utilisation
WO1996003528A3 (fr) * 1994-07-27 1996-04-18 Lynxvale Ltd Oligonucleotides et leur utilisation
EP1015011A1 (fr) * 1997-09-16 2000-07-05 NIELSEN, Peter Eigil Acides nucleiques peptidiques a activite antibacterienne
EP1015011A4 (fr) * 1997-09-16 2003-02-26 Nielsen Peter Eigil Acides nucleiques peptidiques a activite antibacterienne
EP1466988A3 (fr) * 1998-06-11 2006-06-07 Chiron Corporation Gènes et produits d'expression génique régulés de façon différentielle lors du cancer de la prostate

Also Published As

Publication number Publication date
AU8497191A (en) 1992-03-17

Similar Documents

Publication Publication Date Title
EP0288163B1 (fr) Oligodéoxynucléotides comme inhibiteurs de la reproduction des virus et de l'expression des oncogènes
US5264423A (en) Inhibitors for replication of retroviruses and for the expression of oncogene products
US5550111A (en) Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5212295A (en) Monomers for preparation of oligonucleotides having chiral phosphorus linkages
AU653504B2 (en) Oligonucleotide analogs with novel linkages
US5264564A (en) Oligonucleotide analogs with novel linkages
AU669250B2 (en) Method of cleaving specific strands of RNA
US5792615A (en) Synthetic oligomers having chirally pure phoshonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
JPH06511492A (ja) キラルリン結合を有するオリゴヌクレオチド
US6033909A (en) Oligonucleotide analogs, their preparation and use
WO1992020697A1 (fr) Oligonucleotides bloques au niveau de l'extremite 3'
DK174025B1 (da) Anvendelse af visse 2',5'-oligoadenylatanaloger til fremstilling af et lægemiddel mod retrovirusinfektioner, hidtil ukendte blandt en sådan type forbindelser, også til anvendelse ved behandling af en retrovirusinfektion, samt anvendelse af ........
EP0739899B1 (fr) Dérivés d'oligoribonucléotide et leur application comme agents antiviraux
WO1992003127A1 (fr) Compositions et procedes pour le traitement des infections par le vih
AU664883B2 (en) Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
EP1311672B1 (fr) Inhibiteurs de la transcriptase inverse du VIH derivees du tRNA
WO1995031470A2 (fr) Inhibiteurs antisens de l'expression de genes
JPH0578386A (ja) 新規な抗ｈｉｖ剤及びその製造方法
US6130324A (en) Amphipathic oligonucleotides and polynucleotides having potent antiviral activity
AU2001284570A1 (en) New sequences
CA2149626A1 (fr) Formation de complexes trihelicoidaux d'acides nucleiques monocatenaires a l'aide d'oligomeres nucleosidiques contenant des analogues de pyrimidines
WO1999000401A1 (fr) Oligonucleotides 3'-monophosphorylisants
IE83348B1 (en) Therapeutic uses of 2',5'-oligoadenylate derivatives
KR19990022536A (ko) 높은 키랄 순도의 포스포로티오에이트 결합기를 가지는 올리고뉴클레오티드

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/3-3/3,DRAWINGS,REPLACED BY NEW PAGES 1/3-3/3;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载